



The Puerto Rico Chamber of Commerce
and El Nuevo Día present:



Research-Driven Health Policies to Ensure Health Equity

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE




 #tucamaraenaccion

Health Equity is the fair distribution of health determinants, outcomes, and resources within and between segments of the population, regardless of social standing.


World Health Organization

Health equity” implies that everyone should have a fair opportunity to attain their full health potential



Liver Cancer Mortality in US Hispanics


5th Leading
Cause
(6%)



2nd Leading
Cause
(11%)



Age Adjusted Incidence Rates Liver Cancer PR (1987-2012)



Hepatitis C in Puerto Rico

- ✓ 1st Cause of Liver Cancer
- ✓ 1st Cause of Liver Transplant
- ✓ 3% of seroprevalance in PR
- >100,000 infected individuals



Healthy



Cirrhosis

Access to Medicines = Health Equity



NATURE | NEWS


United States to approve potent oral drugs for hepatitis C

Improved treatments offer hope for eradication of viral liver infection.

Sara Reardon

30 October 2013

Rights & Permissions



GOBIERNO DE PUERTO RICO
Administración de Seguros de Salud

Hon. Ricardo A. Rosselló Nevares
Gobernador

Sra. Angella M. Ávila Marrero
Directora Ejecutiva

Carta Normativa 19-0116

16 de enero de 2019

A: Aseguradoras, Compañías de Servicios de Salud Mental, Administrador del Beneficio de Farmacia, Farmacias, Grupos Médicos Primarios y Proveedores Participantes del Plan de Salud del Gobierno

Asunto: Medicamento para Hepatitis C

ASES se encuentra en el proceso de establecer el proceso administrativo y de pago por el medicamento para el tratamiento de Hepatitis C.

Dada la necesidad de facilitar el tratamiento a pacientes trasplantados y con necesidad médica que de lo contrario pudiera ponerse en riesgo la pérdida o función de un órgano, o la vida del paciente estaremos cubriendo efectivo desde el 16 de enero de 2019 como emergencia el siguiente medicamento en lo que se completa el proceso:

Nombre del medicamento que entra al formulario	Nombre de referencia	Guía de Referencia	Formularios
Mavyret® tab.	Glecaprevir and Pibrentasvir	PA	Salud Física

ASES estará pagando directamente a la farmacia por este medicamento a través del PBM contratado por lo que este medicamento no está a riesgo de la aseguradora del paciente. Sin embargo, es importante que la aseguradora sea informada para que pueda actualizar junto con el especialista que atiende el beneficiario el plan de tratamiento de este.

Cordialmente,

Angella M. Ávila Marrero
Directora Ejecutiva

Immuno Therapies in Cancer

Dr. Jim Allison, Nobel Price 2018



APRIL 4, 2016

TIME

What if your
immune system
could be taught
to kill cancer?

**Inside the
brutally
selective,
hugely
expensive,
lifesaving
trials of
immunotherapy.**

By Alice Park

time.com

Anti PDL1 therapy – 1st
cancer agnostic drug

Long term survivor

Complete & partial
responses in Stage IV
Cancers


ORIGINAL ARTICLE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency


D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Lubner, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, and L.A. Diaz, Jr.

Clinical Benefit of Pembrolizumab Treatment According to Mismatch-Repair Status

Le DT et al. N Engl J Med 2015;372:2509-2520.



Ensure Health Equity by Promoting Inclusive Research



Participation of Hispanics in Oncology Clinical Trials is Limited

- FDA requires that pharmaceutical companies submitting applications for new drugs and/or indications for existing drugs to include participants from diverse ethnic and racial backgrounds including Hispanics
- **Less than 5% of all oncology trials include Hispanics**

FDA Oncology Approvals (2017)

2017 Drug Trials Snapshots Summary Statistics

(Jan 1, 2017 - Dec 31, 2017)

Oncology:

7,045 patients participated in trials that led to approvals of 12 new drugs

Demographic Subgroups	Women	White	Asian	Black or African American	Hispanic	Age 65 and Older	United States
Participant Average	83%	74%	12%	2%	4%	26%	34%

<https://www.fda.gov/drugs/informationondrugs/ucm412998.htm>



Expanded Inclusion 2018

The American Society of
Clinical Oncology (ASCO)


Friends of Cancer
Research (Friends)
Advocacy Organization

Oncology Clinical Trials in Puerto Rico

- **5,500** open and recruiting oncology clinical trials in the United States, **53 (1%)** are **conducted in Puerto Rico***
- 32 sponsored or co-sponsored by pharmaceutical industry
- An opportunity to **strengthen oncology clinical trials programs** in Puerto Rico to help fill this gap

Only 1%
Oncology Trials
in PR

Cancer in Puerto Rico



- ✓ 1st cause of death
- ✓ Every year >15,000 new diagnosis of cancers
- ✓ Over 50,000 people living with cancer

Puerto Rico – Clinical Research Ecosystem

- Hispanic population
- Solid infrastructure
 - Universities
 - Health Systems
 - Professionals
 - Pharmaceuticals
- Government Initiative (PRCCI)

Participation in Clinical Trials

Primary reason people *participate* in clinical trials.....**They were asked**

Primary reason people *do not participate* in clinical trials... **They were not asked (not available)**

A photograph of a crowd of people at a public event, many holding Puerto Rican flags. The flags are red, white, and blue with a star and a dove. The background is slightly blurred, showing more flags and people. The text is overlaid on the top left and bottom center of the image.

Close the Health Equity Gap in Puerto Rico

Provide access to approved therapies, measure outcomes, and promote a culture of research-driven health policy and quality.

Puerto Rico Health & Insurance Conference 2019



Puerto Rico Consortium
for Clinical Investigation
invites you to...



SEMANA DE
LA INVESTIGACIÓN
CLÍNICA Y TRASLACIONAL
EN PUERTO RICO 2019



PUERTO RICO 2019 CLINICAL RESEARCH SUMMIT

The 2019 Clinical Research Summit: Connecting the World,
will bring together leaders and key stakeholders from
organizations involved in clinical and translational research.

For Information & Registration

<https://bit.ly/2JlgPp2>



Thank You

Follow us:



www.camarapr.org

[#tucamaraenaccion](https://twitter.com/tucamaraenaccion)